Avastin

Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
Why 2016 drug approvals fell
Why 2016 drug approvals fellWhile FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.
FDA approves expansion of Avastin in ovarian cancerFDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.
Anti-VEGF drugs: Safe and effective for treating DMEData from large randomized trials indicate that diabetic macular edema can be treated safely and effectively with anti-vascular endothelial growth factor therapies.
Oncologists not prescribing expensive cancer drugsIn the latest controversy over the high cost of certain prescription medications, a recent Reuters article said that more oncologists won’t prescribe expensive drugs.
FDA's Avastin rules may not be necessaryWhile FDA is proposing that bevacizumab (Avastin) for macular degeneration be used within 5 days of re-packaging to avoid development of endophthalmitis in patients, that precaution may not be necessary, according to a new study.
Novartis deterred UK physicians from prescribing Avastin, report saysNovartis attempted to block studies in the United Kingdom comparing ranibizumab (Lucentis) and bevacizumab (Avastin) for the treatment of wet age-related macular degeneration (AMD), according to an article published in The BJM, an international peer-reviewed medical journal.
FDA drug approvals-April 2015FDA actions in brief, priority review, breakthrough therapy designation, fast-track designations, orphan drug designations, first-time generic approvals
DME study: Aflibercept injection shows greater gains in visual acuity than alternative anti-VEGF therapiesIn patients with moderate or worse vision loss at baseline, those treated with aflibercept (Eylea, Regeneron) Injection gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative anti-VEGF therapies, according to a study published in the New England Journal of Medicine.
Cancer drugs move to specialty distributors draws protestA national survey of pharmacy professionals released March 3 found that Genentech's decision to move three primary cancer drugs to specialty drug distribution has resulted in higher costs to hospitals and reduced availability of the medications.